Sedation in Intensive Care: Comparison between the 1% and 2% propofol concentrations;Sedacion en Cuidados Intensivos: Comparacion de las concentraciones de propofol al 1% y al 2%

Medicina Intensiva

Volumn 23, Issue 3, 1999, Pages 114-119

  Conejero Garcia Quijada R ^a,e   Garcia De Lorenzo Y Mateos A ^b   Acosta Escribano, J ^d   Lopez Martinez J ^c   Serralta Gomis, M J ^a  

^a Orden Hospitalaria San Juan de Dios   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL SEVERO OCHOA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

Author keywords

Diacepam; Propofol; Sedation

Indexed keywords

ANESTHETIC AGENT; PROPOFOL;

ARTICLE; CRITICAL ILLNESS; HUMAN; INTENSIVE CARE UNIT; SEDATION;

EID: 0032950217     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Anonymous Sedation in the intensive care unit (editorial). Lancet 1984, i: 1.388-1.389.
2. Grounds RM, Lalor JM, Lumley J, Royston D, Morgan M. Propofol infusion for sedation in the intensive care unit: a preliminary report. Br Med J 1987; 294, 397-400.
3. Aitkenhead AR, Willats SM, Park G. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 1989; 2, 704-709.
4. Carrasco C, Molina R, Costa J, Soler JM, Cabré LL. Propofol vs Midazolam in short-medium, and long term sedation of critically ill patients. A cost-benefit analisis. Chest 1993; 103 557-564.
5. Walt I, Ledigham IMA. Mortality among multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984:39 973-981.
6. Clarke RSJ, Fee JPH, Dunde JW. Factors predisponing to hypersensitivity reactions to intravenous anesthetics. Proc R Soc Med 1977, 70: 782-784
7. Fulton B, Sorkin M. Propofol. An overwiew of its pharmacology of its clinical efficacy in intensive care sedation. Drug 1995; 50: 636-657.
8. Kay B, Rolly G. ICI 35868, a new intravenous induction agent Acta Anaesthesiol Belg 1997: 28, 303-316.
9. Wagner BKJ, O'Hara D Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Klin Pharmacotink 1997, 33: 426-453.
10. Zeneca, inc Propofol prescribing information. Wilmington, DE, USA, 1.195
11. Simons PJ, Cockehott DE, Douglas EJ. Disposition in male volunteers of subanesthetic dose of an oil water emulsion of C-propofol. Xenobiotica 1988; 18: 429-440.
12. Sebel PS. Propofol a new intravenous anesthetic. Anaesthesiology 1989; 71: 260-263.
13. Farling PA, Johnsto JR, Copel DL. Propofol infusion for sedation of patients whit head injury in intensive care. A preliminary report. Anesthesia 1989; 44: 222-226.
14. Mirenda J, Broyles G. Propofol as used for sedation in the ICU. Chest 1995; 108: 539-548.
15. 2 reactivity of brain vessels in the human. Anaesthesit 1987; 36: 60-65.
16. Stecker MM, Kramer TH, Raps EC, Omeeghan R, Dulaney E, Skaar DJ. Treatment of refractory Status Epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39(1): 18-26.
17. Goodman NW, Black AMS, Carter JA. Some ventilatory effects of propofol as sole anesthetic agent. Br J Anaesth 1987; 59: 1.497-1.503.
18. Corti G, Dell Utri D, Vilardi V. Propofol induces bronchodilatation in mechanically ventilated chronic obstructive pulmonary disease (COPD) patients: Acta Aneaesthesiol Scand 1993; 37: 105-109.
19. Keaveny JP, Knell PJ. Intubation under induction doses of propofol. Anaesthesia 1988; 43S: 80-81.
20. Borgeat A, Wilder-Smith OGH. Adjuvant propofol for refractory cisplatin associated nausea and vomiting. Lancet 1992; 340: 679-680
21. Borgeat A, Wilder-Smith OGH, Mentha G. Propofol and cholestatic pruritis. Am J Gastroenterol 1992; 87: 672-673.
22. MacKenzie SJ, Kapadian F, Grant IS. Propofol infusion for control of status epilepticus. Anaesthesia 1990; 45: 1.043-1.104.
23. Rouse EC. Propofol for electroconclusive therapy. Anaesthesia 1988; 43S: 61-64.
24. Weinbroum AA, Halpern P, Rudick V, Sorkine P, Freedman M. Midazolam versus propofol for long-term sedation in the ICU: A prospective randomized comparison. Intensive Care Med 1997; 23: 1.258-1.263.
25. Ronan KP, Gallagher TJ, George B, Hamby B. Comparison of propofol and midazolam for sedation in intensive care unit patients. Crit Care Med 1995; 23: 286-293.
26. Barrientos R, Sánchez MM, Morales C, Robas A, Cuena R, Ayensa A. Prolonged sedation of critically ill patients with midazolam or propofol: Impact on weaning and costs. Crit Care Med 1997, 25: 33-40.
27. Chamorro C, de Latorre F, Montero A, Sánchez-Izquierdo JA, Jareño A, Moreno JA, et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: Results of a prospective, randomized, multicenter trial. Crit Care Med 1996; 24: 932-939.
28. García de Lorenzo A, Ortiz Leyba C, y Grupo de Metabolismo y Nutrición de la SEMIUC. II Conferencia de Consenso: Respuesta a la agresión: Valoración e implicaciones terapéuticas. Med Intensiva 1997; 21: 13-28.
29. Durrington PN, Miller JP. Clinical aspects of hyperlipidemia. Br J Hosp Med 1984; 32: 28-34.
30. Pestaña D, García de Lorenzo A, Madero R. Metabolic pattern and lipid oxidation during abdominal surgery: Midazolam versus Propofol. Anesth Analg 1996; 83: 837-843.
31. Barton RG. Nutrition support in critical illness. Nutr Clin Pract 1994; 9: 127-139.
32. Beutler B, Cerami A. Recombinant interleukin-1 suppress lipoprotein lipase activity in 3T3-L cells. J Immunol 1985; 135: 3.969-3.971.
33. Pomposelli JJ, Flores EA, Bistrian BR. Role of biochemical mediators in clinical nutrition and surgical metabolism. JPEN 1988; 12: 212-218.
34. Gagner M, Shizgal HM, Forse RA. The effect of interleukin-1 and interleukin-2 on the adrenergic control of hormone-sensitive lipase in the human adypocite. Surgery 1986; 100: 298-305.
35. Lindholm M. The ability of critically ill patients to eliminate fat emulsions. Drug Development 1991; 4(S): 40-42.
36. Carpentier YA. Are present fat emulsions appropriate? En: Wilmore DW, Carpentier YA, eds. Metabolic support of the critically ill patient. Berlin: Springer-Verlag, 1993; 157-171.
37. Eddleston JM, Shelly MP. The effect on serum lipid concentrations of a prolonged infusion of propofol. Intensive Care Med 1991; 17: 424-426.
38. McLeod G, Dick J, Wallis C, Patterson A, Cox C, Colvin J. Propofol 2% in critically ill patients: Effect on lipids. Crit Care Med 1997; 25: 1.976-1.981.
39. Díaz D, Vaquero C, Quintana M, Añón JM, López Martínez J, García de Lorenzo A Propofol 1% vs 2%: Eficacia, posología y tolerancia metabólica en el paciente politraumatizado. Med Intensiva 1998, 22(Supl 1): 109
40. Montanini S, Practico C, Leone D, Tufano R, Pagliarulo R, Bruno F, et al Confronto tra la formulazione di propofol all' 1% e la formulazione al 2% nella sedazione in terapia intensiva. Minerva Anestesiologica 1995: 61(S): 85-88.
41. Barrientos R. Nuevas perspectivas de la sedación prolongada de pacientes críticos con Diprivan 2%. Nuevas perspectivas de la sedación: Ventajas clínicas. Madrid: Zéneca, 1998: 23-27.
42. Peck MD. Omega-3 polyunsaturated fatty acids: Benefit or harm during sepsis? New Horizons 1994; 2: 230-236.
43. Ulevitch RJ, Tobias PS, Mathison JC. Regulation of the host response to bacterial lipopolysaccharides. Fed Proc 1984; 43: 2.755-2.759.
44. Parker CW. Lipid mediators produced through the lipoxygenase pathway. Annu Rev Immunol 1987; 5: 65-84.
45. García de Lorenzo A, Culebras JM. Ácido linoleico y sistema inmune. Controversias sobre las emulsiones lipídicas. Nutr Hosp 1992; 7: 377-387.
46. Lowry SF, Thompson WA III. Nutrient modification of inflammatory mediator production New Horizons 1994, 2: 164-174.
47. Van de Velde M, Wouters PF, Rolf N, Van Aken H, Vandermeersch E. Comparative hemodynamic effects of three different parenterally administered lipid emulsions in conscious dogs. Crit Care Med 1998; 26: 132-137.
48. Dewandre J, Van Bos R, Van Hemelrijck J, Van Aken H. A comparison of the 2% and 1% formulations of propofol during anaesthesia for craniotomy. Anaesthesia 1994; 49: 8-12.
49. Servin FS, Desmonts JM, Melloni C, Martinelli G. A comparison of 2% and 1% formulations of propofol for the induction and maintainance of anaesthesia in surgery of moderate duration. Anaesthesia 1997, 52: 1.216-1.221.
50. Ewart MC, Yau KW, Morgan M. 2% propofol for sedation in the intensive care unit. A feasibility study. Anaesthesia 1992; 47: 146-148.
51. Dunham CM, Frankenfield D, Belzberg H, Wiles CE, Cushing B, Grant Z. Inflammatory markers: superior predictors of adverse outcome in blunt trauma patients. Crit Care Med 1994; 22, 667-672.
52. López Martínez J, Moreno Porras I, Díaz Abad R. Rodríguez Roldán JM, Jiménez Martín MJ, Del Nogal Saez F. Hipertrigliceridemia en el síndrome de respuesta inflamatoria (SIRS). Incidencia y factores asociados. Med Intensiva 1998; 22 (supl 1) 99.
53. López Martínez J, Sánchez Castilla M, Ordóñez González FJ, Temprano Vázquez S, García de Lorenzo A. Del Nogal Sáez F. Utilidad del colesterol como marcador nutrometabólico en el paciente séptico. Nutr Hosp 1995; 10: 24-31.
54. López Martínez J, Sánchez Castilla M, Temprano Vázquez S, Algora Weber A, Jiménez Jiménez J, Del Nogal Sáez F. Metabolismo del hierro en el paciente crítico. Med Intensiva 1995; 16: 285-292.
55. Celaya Pérez S, Núñez Ruiz R, Sánchez Álvarez MC. Indicaciones del soporte nutricional en UCI Elección de la vía de aporte de nutrientes. En: Guías de práctica clínica en Medicina Intensiva. Madrid: SEMIUC, 1996; bloque temático V: 1-7.
56. Murphy PG, Myers DS, Davies MJ, Webster NR, Jones JG. The antioxidant potential of propofol (2,6 diisopropylphenol). Br J Anaesthesiol 1992, 68: 613-618.
57. Murphy PG, Bennet JR, Myers DS, Davies MJ, Jones JG. The effect of propotol anaesthesia on free radical-induced lipid peroxidation in rat liver microsomes. Eur J Anaesthesiol 1993; 10: 261-266.
58. Aarts L, van der Hee R, Dekker I, de Jong J, Langemeijer H, Bast A The widely used anesthetic agent propofol can replace alfa-tocopherol as an antioxidant FEBS ett 1995; 357: 83-85.
59. Kokita N, Hara A Propofol attenuates hydrogen peroxide-induced mechanical and metabolic derangements in the isolated rat heart. Anesthesiology 1996; 84: 117-127.